Secondary malignant neoplasm of brain and cerebral meninges
ICD-10 C79.3 is a billable code used to indicate a diagnosis of secondary malignant neoplasm of brain and cerebral meninges.
C79.3 refers to secondary malignant neoplasms that have metastasized to the brain and cerebral meninges from a primary tumor located elsewhere in the body. This condition is characterized by the presence of malignant cells in the brain or its protective membranes, which can arise from various primary cancers, including lung, breast, melanoma, and others. The clinical presentation may include neurological deficits, headaches, seizures, and changes in mental status, depending on the location and extent of the metastasis. Diagnosis typically involves imaging studies such as MRI or CT scans, along with histopathological confirmation through biopsy. Staging of metastatic brain tumors is crucial for treatment planning and prognosis, often utilizing the TNM (Tumor, Node, Metastasis) system, although specific staging for brain metastases may differ. Palliative care considerations are essential, focusing on symptom management and quality of life, especially in advanced disease stages where curative treatment is not feasible. Multidisciplinary approaches involving oncologists, neurologists, and palliative care specialists are often employed to address the complex needs of these patients.
Detailed history of the primary cancer, treatment history, and imaging results.
Patients with known primary cancers presenting with neurological symptoms.
Ensure accurate staging and documentation of treatment plans.
Neurological assessments, imaging findings, and symptomatology.
Patients presenting with seizures or cognitive changes due to metastasis.
Document neurological deficits and their impact on daily functioning.
Used to evaluate for brain metastases in patients with known primary cancers.
Document indications for the scan and findings.
Oncologists and neurologists should collaborate on imaging findings.
Accurate coding of C79.3 is crucial for appropriate treatment planning, reimbursement, and understanding the epidemiology of metastatic brain tumors. It ensures that patients receive the necessary care and resources based on their specific diagnosis.
